What are the recent trends in market size and growth for the inhalation cdmo market?
The inhalation CDMO market size has grown strongly in recent years. It will grow from $2.08 billion in 2024 to $2.23 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to rising prevalence of respiratory disorders, growing demand for personalized medicine, increasing outsourcing by pharmaceutical companies, growth of the biopharmaceutical industry.
The inhalation CDMO market size is expected to see strong growth in the next few years. It will grow to $2.9 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to focus on precision medicine and targeted therapies, rapid expansion of biopharmaceutical inhalation therapies, focus on patient-centric solutions, global market expansion and emerging market opportunities, regulatory support for inhalation drug development. Major trends in the forecast period include increasing demand for digital health solutions, biologic inhalation therapies, focus on sustainable inhaler technologies, integration of artificial intelligence (AI) and machine learning, collaborations and partnerships.
Get Your Free Sample of The Global Inhalation CDMO Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13864&type=smp
Which major factors have contributed to the expansion of the inhalation cdmo market?
The increasing prevalence of respiratory disorders is expected to propel the growth of the inhalation CDMO market going forward. Respiratory disorders are a group of medical conditions that affect the respiratory system, which includes the organs and structures involved in breathing. Inhalation CDMOs are used in the development and manufacturing of products for respiratory disorders due to their expertise in formulating and delivering drugs to the lungs, offering specialized expertise, infrastructure, and resources to pharmaceutical companies seeking to bring innovative inhalation therapies. For instance, according to the Australian Bureau of Statistics (ABS) an Australia-based Government agency, 8.5 million Australians (34%) reported having chronic respiratory conditions, including 2.8 million people (11%) with asthma and 638,000 people (2.5%) with COPD. Therefore, the increasing prevalence of respiratory disorders is driving the growth of the inhalation CDMO market.
How is the inhalation cdmo market segmented?
The inhalation CDMO market covered in this report is segmented –
1) By Product: Dry Powder Inhaler (DPIs), Metered Dose Inhaler (MDIs), Nebulizer, Soft Mist Inhaler
2) By Disease Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Acute Respiratory Distress Syndrome, Pulmonary Fibrosis
3) By Technology: Manual Inhalers (SMI), Digital Inhalers
4) By End-User: Big Pharmaceutical Companies, Small and Medium-sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Other End-Users
Subsegments:
1) By Dry Powder Inhaler (DPIs): Capsule-Based DPIs, Diskus-Style DPIs, Multi-Dose DPIs, Unit-Dose DPIs
2) By Metered Dose Inhaler (MDIs): Pressurized MDIs (pMDIs), Breath-Actuated MDIs, Soft Mist MDIs
3) By Nebulizer: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Portable Nebulizers
4) By Soft Mist Inhaler: Respimat Inhalers, Other Soft Mist Inhalation Devices
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report
Who are the top competitors in the inhalation cdmo market?
Major companies operating in the inhalation CDMO market report are Pfizer Inc., Merck KGaA, Baxter’s BioPharma Solutions, Lonza Group AG, Catalent Inc., AptarGroup Inc., Samsung Biologics Co. Ltd., Siegfried Holding AG, Recipharm AB, Stevanato Group SpA, Cambrex Corporation, CordenPharma, Nemera, Hovione FarmaCiencia SA, Vectura Group Ltd., CARBOGEN AMCIS, Kindeva Drug Delivery Ltd., Frontage Laboratories Inc, Formosa Laboratories Inc, Sanner GmbH, H&T Presspart Ltd., Astech Projects Ltd, Cliantha Research, Dipharma Francis Srl, Copley Scientific
Which key trends are expected to influence the inhalation cdmo market in the coming years?
Major companies operating in the inhalation CDMO industry are adopting a strategic partnership approach to provide specialized drug development and delivery. A strategic partnership is a long-term, mutually beneficial arrangement between two or more companies that work together to achieve shared goals. For instance, in May 2023, Hovione, a Portugal-based Contract Development and Manufacturing Organization, partnered with H&T Presspart, a UK-based manufacturer of high-precision metal and plastic components for the pharmaceutical industry, to develop Presspart’s Sunrise Capsule-based Dry Powder Inhaler platform. This partnership focuses on developing new technologies that can deliver higher doses of drugs and improve the efficiency of drug delivery to the lungs.
Which regional trends are influencing the inhalation cdmo market, and which area dominates the industry?
North America was the largest region in the inhalation contract development and manufacturing organization (CDMO) market in 2024. The regions covered in the inhalation CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Inhalation CDMO Market Report 2025 Offer?
The inhalation cdmo market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
An inhalation contract development and manufacturing organization (CDMO) is a specialized organization that provides comprehensive services to pharmaceutical and biotechnology firms for the development and manufacturing of inhalable drugs. These organizations offer a range of services tailored specifically to the needs of inhalation products, including formulation development, analytical testing, process optimization, scale-up, and commercial manufacturing.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13864
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
